araag2/HINT huggingface dataset:
Clinical trial NCT00184548 (phase 3, status: terminated)
Conditions: acquired bleeding disorder, trauma
ICD codes: D68.311, L85.0, H53.62, I77.0, L11.0, L68.1, N48.83, K08.81, K08.82, O71.9, N48.31, O71.89, G89.11, G89.21
Drugs: eptacog alfa (activated), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    see termination reason in detailed description
  
Eligibility criteria:

        Inclusion Criteria:

          -  Trauma injury (blunt and/or penetrating) with evidence of active hemorrhage (torso
             and/or proximal lower extremity) refractory to blood component therapy and surgical
             haemostatic procedures at the time of randomisation
Clinical trial NCT00003814 (phase 3, status: completed)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: eflornithine
SMILES: NCCC[C@@](N)(C(F)F)C(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed low grade (grade 1 or 2), superficial
        (stage Ta or T1) transitional cell carcinoma (TCC) of the bladder Newly diagnosed or
        recurrent All visible tumor must have been resected within the past 12 weeks Standard
        clinical management determined to be expectant observation without further surgery,
        intravesical therapy, or systemic therapy No prior upper tract TCC No history of grade 3
        TCC, carcinoma in situ including severe dysplasia, non-TCC histology, or TCC greater than
        or equal to T2 No involvement of upper urinary tract prior to or at the time of initial
        tumor resection Abdominal CT scan, IVP, or retrograde pyelogram within the past 3 months to
        rule out upper urinary tract tumor

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not
        specified Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use
        effective contraception No prior malignancy within the past 5 years and no concurrent
        malignancy except nonmelanomatous skin cancer or carcinoma in situ of the cervix No
        clinically significant hearing loss (i.e., hearing loss effects everyday life and/or wears
        a hearing aide) No other significant medical or psychiatric condition

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior growth factors No
        concurrent growth factors Chemotherapy: No prior systemic chemotherapy for bladder cancer
        No concurrent intravesical therapy At least 4 weeks since prior chemotherapy No concurrent
        chemotherapy Endocrine therapy: At least 4 weeks since prior high dose steroids or
        prednisone No concurrent high dose steroids No concurrent prednisone or its equivalent in
        excess of 10 mg/day Radiotherapy: No prior radiotherapy for bladder cancer At least 4 weeks
        since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics
        Other: At least 4 weeks since prior carbamazepine or experimental drugs No concurrent
        carbamazepine or experimental drugs
Clinical trial NCT01737697 (phase 3, status: completed)
Conditions: hyperkalemia
ICD codes: E87.5, P74.31
Drugs: zirconium silicate (acute phase), zirconium silicate (subacute phase), placebo (acute phase), placebo ( subacute phase)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of written informed consent.

          -  Over 18 years of age.

          -  Mean i-STAT potassium values between 5.0 - 6.5 mmol/l inclusive, at screening (Study
             Day 0).

          -  Ability to have repeated blood draws or effective venous catheterization.

          -  Women of childbearing potential must be practicing a highly effective method of birth
             control.

        Exclusion Criteria:

          -  Pseudohyperkalemia signs and symptoms, such as excessive fist clinching hemolyzed
             blood specimen, severe leukocytosis or thrombocytosis.

          -  Subjects treated with lactulose, xifaxan or other nonabsorbed antibiotics for
             hyperammonemia within the last 7 days.

          -  Subjects treated with resins (such as Sevelamer acetate or Sodium polystyrene
             sulfonate [SPS; e.g. Kayexalate®]), calcium acetate, calcium carbonate, or lanthanum
             carbonate, within the last 7 days.

          -  Subjects with a life expectancy of less than 3 months.

          -  Subjects who are HIV positive.

          -  Subjects who are severely physically or mentally incapacitated and who in the opinion
             of investigator are unable to perform the subjects' tasks associated with the
             protocol.

          -  Women who are pregnant, lactating, or planning to become pregnant.

          -  Subjects with Ketoacidosis/Acidemia.

          -  Presence of any condition which, in the opinion of the investigator, places the
             subject at undue risk or potentially jeopardizes the quality of the data to be
             generated.

          -  Known hypersensitivity or previous anaphylaxis to ZS or to components thereof.

          -  Previous treatment with ZS

          -  Treatment with a drug or device within the last 30 days that has not received
             regulatory approval at the time of study entry.

          -  Subjects with cardiac arrhythmias that require immediate treatment.

          -  Insulin-dependent diabetes mellitus

          -  Subjects on dialysis
Clinical trial NCT01008553 (phase 3, status: completed)
Conditions: postherpetic neuralgia, complex regional pain syndromes (crps), postoperative pain
ICD codes: B02.22, G90.50, G90.511, G90.512, G90.513, G90.519, G90.521, G90.522
Drugs: fentanyl, placebo
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants whose pain because of post-herpetic neuralgia, Complex Regional Pain
             Syndrome (CRPS) or post-operative pain syndrome is continuing for at least 12 weeks
             prior to informed consent

          -  Participants who are continuously taking a non-opioid analgesic at the normal highest
             dose or more for at least 14 consecutive days prior to informed consent, or at a
             certain dose (except the use on an as-needed base) on consecutive days or participants
             who are continuously taking an analgesic adjuvant with a certain dosage and
             administration (except the use on an as-needed base) for at least 14 consecutive days
             prior to informed consent

          -  Participants showing insufficient therapeutic efficacy of the non-opioid analgesic
             currently being used, and to requiring a continuous opioid analgesic as per the
             Investigator or Sub-investigator

          -  Participants with an average pain intensity of 50 millimeter or more on the Visual
             Analog Scale in 24-hour daily living prior to informed consent

          -  Participants who can be hospitalized to the 4th day after the initiation of titration
             period

        Exclusion Criteria:

          -  Participants who had an operation that may affect the assessment within 30 days before
             informed consent

          -  Participants whose main cause of the pain to be assessed is considered attributable to
             psychogenic pain (physical pain that is caused, increased, or prolonged by mental,
             emotional, or behavioral factors)

          -  Participants with asthma, bradyarrhythmia (slow irregular heart beat) and severe
             respiratory function disorders

          -  Participants complicated with hepatic dysfunction such as fulminant hepatitis
             (inflammation of the liver) and liver cirrhosis (serious liver disorder in which
             connective tissue replaces normal liver tissue, and liver failure often occurs), or
             renal impairment such as nephritic syndrome, acute renal failure, and chronic renal
             failure

          -  Participants with a history of hypersensitivity to fentanyl and other opioid
             analgesics
Clinical trial NCT00254735 (phase 3, status: completed)
Conditions: obsessive compulsive disorder
ICD codes: F42.8, F42.9, F60.5
Drugs: quetiapine fumarate, ssri/clomipramine
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CN(C)CCCN1C2=CC=CC=C2CCC2=C1C=C(Cl)C=C2
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent, men and women aged ³18 to £65 years with diagnosis of OCD, at
             least 12 weeks of treatment with SSRI or clomipramine

        Exclusion Criteria:

          -  Substance abuse or dependence, female patients who are pregnant, lactating or at risk
             of pregnancy, known intolerance or lack of response to quetiapine, use of
             antihypertensive medication with changing doses
Clinical trial NCT00410072 (phase 3, status: completed)
Conditions: hepatitis b, chronic
ICD codes: B18.0, B18.1, B18.2, B18.8, B18.9
Drugs: entecavir, entecavir + tenofovir
SMILES: CCOC(=O)C1=CC=C(N)C=C1, [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic hepatitis B virus (HBV) infection (hepatitis B e antigen [HbeAg]-positive or
             negative) disease

          -  Nucleoside- and nucleotide-naive

          -  Males or females ≥16 years of age (or minimum age of consent in a given country)

          -  Compensated liver function

          -  HBV DNA >1.72*10*5*IU/mL (approximately 10*6*copies/mL) for HbeAg-positive
             participants

          -  HBV DNA >1.72*10*4*IU/mL (approximately 10*5*copies/mL) for Hbe-Ag-negative
             participants

          -  Alanine aminotransferase level ≥*upper limit of normal (ULN) and ≤10*ULN

        Exclusion Criteria:

          -  Evidence of decompensated cirrhosis

          -  Coinfection with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus

          -  Laboratory values out of protocol-specified range
Clinical trial NCT01751867 (phase 3, status: completed)
Conditions: myelodysplastic syndrome
ICD codes: D46.9, D46.C, D46.Z
Drugs: decitabine at 15 mg/m2, decitabine at 20 mg/m2
SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O, CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must have diagnosed with Myelodysplastic Syndrome (MDS) denovo (previously not
             present) or secondary as per the classification of French-American-British (FAB) and
             International Prognostic Scoring System (IPSS) greater than or eaul to 0.5 as
             determined by complete blood count (CBC), bone marrow assessment and bone marrow
             cytogenetics

          -  Must have an Eastern Oncology Cooperative Group (ECOG) performance status of 0-2

          -  Must have adequate hepatic and renal function as measured by the aspartate
             transaminase (AST), alanine transaminase (ALT), total bilirubin and serum creatinine,
             respectively

          -  Must have recovered from all toxic effects of prior therapy and not received any
             chemotherapy for a minimum of 4 weeks (6 weeks if the patient has been treated with a
             nitrosoureas) prior to the first dose of study drug - Woman must be postmenopausal, or
             surgically sterile, or abstinent, or, if sexually active, be practicing an effective
             method of birth control (eg, oral contraceptives, contraceptive injections,
             intrauterine device, double-barrier method, contraceptive patch, male partner
             sterilization)

        Exclusion Criteria:

          -  Must not have a diagnosis of acute myeloid leukemia (greater than 30% bone marrow
             blasts) - Must not have received radiotherapy within 14 days before the first dose of
             study drug - Must not have any other prior cancer, other than superficial bladder
             cancer, basal cell skin and cervical cancer - Must not have associated autoimmune
             hemolytic anemia or immune thrombocytopenia and inaspirable bone marrow - Must not
             have a mental illness or any other condition (eg, uncontrolled cardiac or pulmonary
             disease, diabetes), that could prevent full cooperation with the study requirements.
Clinical trial NCT00052299 (phase 3, status: completed)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: cytarabine, etoposide, gemtuzumab ozogamicin, idarubicin, mitoxantrone hydrochloride
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of acute myeloid leukemia (AML)

               -  Bone marrow blasts at least 20% by bone marrow aspiration or biopsy

               -  FAB subtypes M0-M2 and M4-M7

                    -  No acute promyelocytic leukemia (FAB subtype M3)

          -  Previously untreated primary or secondary AML, including AML after myelodysplastic
             syndromes

               -  Hydroxyurea and/or corticosteroid therapy for no more than 14 days allowed

          -  No blast crisis of chronic myelogenous leukemia

          -  No AML supervening after other myeloproliferative diseases

          -  No active CNS leukemia

        PATIENT CHARACTERISTICS:

        Age

          -  61 to 75

        Performance status

          -  WHO 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC less than 30,000/mm^3 (pretreatment with hydroxyurea for no more than 14 days
             allowed)

        Hepatic

          -  Bilirubin no greater than 3 times upper limit of normal (ULN)

        Renal

          -  Creatinine no greater than 3 times ULN

        Cardiovascular

          -  No concurrent severe cardiovascular disease

          -  No arrhythmias requiring chronic treatment

          -  No congestive heart failure

          -  No symptomatic ischemic heart disease

        Pulmonary

          -  No severe pulmonary dysfunction (CTC grade 3-4)

        Other

          -  HIV negative

          -  No other uncontrolled infection

          -  No other concurrent malignant disease

          -  No severe concurrent neurological or psychiatric disease

          -  No prior alcohol abuse

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent hematopoietic growth factors (filgrastim [G-CSF] or sargramostim
             [GM-CSF]) except for life-threatening infection due to neutropenia

        Chemotherapy

          -  See Disease Characteristics

        Endocrine therapy

          -  See Disease Characteristics

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  No prior enrollment in this trial
Clinical trial NCT00134966 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
SMILES: C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Aged 30 to 80 years, inclusive, at time of Parkinson's disease diagnosis

          -  Idiopathic Parkinson's disease with at least 2 cardinal signs of disease: resting
             tremor, bradykinesia or rigidity

          -  Parkinson's disease impairment warranting treatment with a levodopa formulation
             according to the investigator's assessment

        Exclusion Criteria:

          -  History, signs or symptoms suggesting the diagnosis of atypical or secondary
             Parkinsonism due to drugs, metabolic disorders, encephalitis or other
             neurodegenerative diseases

          -  History of stereotaxic brain surgery for PD (e.g., pallidotomy, deep brain
             stimulation, tissue transplant)

          -  Diagnosis of Parkinson's disease for more than 5 years prior to Screening

          -  Previous use of levodopa in any formulation, entacapone or tolcapone for more than 30
             days or anytime within 4 weeks (28 days) prior to baseline

          -  Use of a dopamine agonist within 4 weeks (28 days) prior to baseline
Clinical trial NCT00143130 (phase 3, status: completed)
Conditions: seizures
ICD codes: G40.89, R56.1, F44.5, G40.501, G40.509, G40.111, G40.119
Drugs: pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  met the inclusion/exclusion criteria for A0081005

          -  have completed the 21-week study and have shown a significant clinical response and
             wish to continue treatment

        Exclusion Criteria:

          -  Having a treatable cause of seizure.

          -  Having a progressive neurological or systemic disorder
Clinical trial NCT00121303 (phase 3, status: completed)
Conditions: leukemia, myelodysplastic syndromes
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, D46.9, D46.C, D46.Z
Drugs: cytarabine, daunorubicin hydrochloride, gemtuzumab ozogamicin
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(C)=O)C(O)=C1C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed diagnosis of 1 of the following:

               -  Acute myeloid leukemia (AML)

                    -  M0-M2 or M4-M7 FAB subtype

                         -  No AML with cytogenetic abnormality t(15;17) (M3)

                    -  Patients with secondary AML progressing from prior myelodysplasia* or
                       biphenotypic leukemia are eligible

               -  Refractory anemia with excess blasts (RAEB) or RAEB in transformation

                    -  International Prognostic Scoring System score ≥ 1.5 NOTE: *Any prior
                       hematological disease of ≥ 4 months duration

          -  No chronic myelogenous leukemia in blastic crisis

          -  No prior polycythemia rubra vera

          -  No primary myelofibrosis

        PATIENT CHARACTERISTICS:

        Age

          -  61 and over

        Performance status

          -  WHO 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  ALT and/or AST ≤ 2.5 times upper limit of normal (ULN)*

          -  Bilirubin ≤ 2 times ULN* NOTE: *Unless elevation is caused by organ infiltration by
             AML

        Renal

          -  Creatinine ≤ 2 times ULN* NOTE: *Unless elevation is caused by organ infiltration by
             AML

        Cardiovascular

          -  No myocardial infarction within the past 6 months

          -  LVEF > 50% by MUGA, echocardiogram, or other methods

          -  No unstable angina

          -  No unstable cardiac arrhythmia

          -  No severe and/or uncontrolled hypertension

        Other

          -  No uncontrolled diabetes

          -  No severe and/or uncontrolled infection

          -  No other severe and/or uncontrolled medical condition

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  More than 6 months since prior chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  No prior induction therapy for AML or myelodysplastic syndromes
Clinical trial NCT00319020 (phase 3, status: completed)
Conditions: pulmonary arterial hypertension
ICD codes: I27.21
Drugs: bosentan
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent by the parents or the legal representatives.

          -  Patients who completed the FUTURE 1 study.

          -  Patients who tolerated bosentan pediatric formulation and for whom bosentan is
             considered beneficial at the end of FUTURE 1.

          -  Males or females >= 2 and < 12 years of age at enrollment in FUTURE 2 (this study).
             Females who are menstruating must have a negative pregnancy test. A reliable method of
             contraception must be considered, if appropriate.

        Exclusion Criteria:

          -  Intolerance to bosentan despite dose reductions.

          -  Any clinically significant laboratory abnormality that precludes continuation of
             bosentan therapy.

          -  Pregnancy or breast-feeding.

          -  Known hypersensitivity to bosentan or any of the excipients.

          -  Premature and permanent study drug discontinuation during FUTURE 1.
Clinical trial NCT00149201 (phase 3, status: completed)
Conditions: gastric cancer, neoplasm metastasis
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: 5-fu continuous infusion, mtx + 5-fu sequential therapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          1. histologic confirmation of gastric adenocarcinoma

          2. inoperable metastatic disease or recurrent metastatic disease after surgery

          3. disease with peritoneal metastasis

          4. 20 years or more but less than 75 years

          5. performance status 2 or less on the Eastern Cooperative Oncology Group scale

          6. no prior treatment for gastric carcinoma except for surgery and adjuvant chemotherapy

          7. no prior chemotherapy or radiotherapy for other disease except for gastric cancer

          8. adequate bone marrow function, adequate liver function, and adequate renal function

          9. no prior transfusion for anemia

         10. provision of written informed consent

        Exclusion Criteria:

          1. Massive pleural effusion

          2. brain metastasis with symptoms

          3. severe diarrhea

          4. other severe medical conditions (infection, diabetes, hypertension, acute myocardial
             infarction, unstable angina, liver cirrhosis, intestinal pneumonia, pulmonary
             fibrosis)

          5. other active malignancies
Clinical trial NCT00332202 (phase 3, status: completed)
Conditions: non hodgkin lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: enzastaurin, placebo
SMILES: CN1C=C(C2=CC=CC=C12)C1=C(C(=O)NC1=O)C1=CN(C2CCN(CC3=CC=CC=N3)CC2)C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of diffuse large B cell lymphoma

          -  Recently completed R-CHOP therapy and achieved remission

          -  International Prognostic Index (IPI) score 3,4,5

          -  At least 18 years of age

          -  Agree to study follow-up schedule

        Exclusion Criteria:

          -  Have received therapy other than R-CHOP for lymphoma

          -  Serious medical condition such as infection,second cancer,heart disease

          -  Received radiation to more than one lesion

          -  Unable to swallow tablets